» Articles » PMID: 24489845

Diabetes Mellitus and the Risk of Alzheimer's Disease: a Nationwide Population-based Study

Overview
Journal PLoS One
Date 2014 Feb 4
PMID 24489845
Citations 123
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Possible association between diabetes mellitus (DM) and Alzheimer's disease (AD) has been controversial. This study used a nationwide population-based dataset to investigate the relationship between DM and subsequent AD incidence.

Methods: Data were collected from Taiwan's National Health Insurance Research Database, which released a cohort dataset of 1,000,000 randomly sampled people and confirmed it to be representative of the Taiwanese population. We identified 71,433 patients newly diagnosed with diabetes (age 58.74 ± 14.02 years) since January 1997. Using propensity score, we matched them with 71,311 non-diabetic subjects by time of enrollment, age, gender, hypertension, hyperlipidemia, and previous stroke history. All the patients were followed up to December 31, 2007. The endpoint of the study was occurrence of AD.

Results: Over a maximum 11 years of follow-up, diabetic patients experienced a higher incidence of AD than non-diabetic subjects (0.48% vs. 0.37%, p<0.001). After Cox proportional hazard regression model analysis, DM (hazard ratio [HR], 1.76; 95% confidence interval [CI], 1.50-2.07, p<0.001), age (HR, 1.11; 95% CI, 1.10-1.12, p<0.001), female gender (HR, 1.24; 95% CI, 1.06-1.46, p=0.008), hypertension (HR, 1.30; 95% CI, 1.07-1.59, p=0.01), previous stroke history (HR, 1.79; 95% CI, 1.28-2.50, p<0.001), and urbanization status (metropolis, HR, 1.32; 95% CI, 1.07-1.63, p=0.009) were independently associated with the increased risk of AD. Neither monotherapy nor combination therapy with oral antidiabetic medications were associated with the risk of AD after adjusting for underlying risk factors and the duration of DM since diagnosis. However, combination therapy with insulin was found to be associated with greater risk of AD (HR, 2.17; 95% CI, 1.04-4.52, p=0.039).

Conclusion: Newly diagnosed DM was associated with increased risk of AD. Use of hypoglycemic agents did not ameliorate the risk.

Citing Articles

Insulin signaling disruption exacerbates memory impairment and seizure susceptibility in an epilepsy model with Alzheimer's disease-like pathology.

Alves S, Servilha-Menezes G, Rossi L, Cortes de Oliveira J, Grigorio-de-SantAna M, Sebollela A J Neural Transm (Vienna). 2025; .

PMID: 39987343 DOI: 10.1007/s00702-025-02896-1.


Associations Between Diabetes Mellitus and Neurodegenerative Diseases.

Szablewski L Int J Mol Sci. 2025; 26(2).

PMID: 39859258 PMC: 11765393. DOI: 10.3390/ijms26020542.


Mitochondria and the Repurposing of Diabetes Drugs for Off-Label Health Benefits.

Yip J, Chiang G, Lee I, Lehming-Teo R, Dai K, Dongol L Int J Mol Sci. 2025; 26(1.

PMID: 39796218 PMC: 11719901. DOI: 10.3390/ijms26010364.


Metabolic and Immune System Dysregulation: Unraveling the Connections between Alzheimer's Disease, Diabetes, Inflammatory Bowel Diseases, and Rheumatoid Arthritis.

Doroszkiewicz J, Mroczko J, Winkel I, Mroczko B J Clin Med. 2024; 13(17).

PMID: 39274269 PMC: 11396443. DOI: 10.3390/jcm13175057.


Islet amyloid polypeptide fibril catalyzes amyloid-β aggregation by promoting fibril nucleation rather than direct axial growth.

Song Z, Tang H, Gatch A, Sun Y, Ding F Int J Biol Macromol. 2024; 279(Pt 1):135137.

PMID: 39208885 PMC: 11469950. DOI: 10.1016/j.ijbiomac.2024.135137.


References
1.
Roberts J, Tersegno S . Estimating and disclosing the risk of developing Alzheimer's disease: challenges, controversies and future directions. Future Neurol. 2010; 5(4):501-517. PMC: 2941213. DOI: 10.2217/fnl.10.31. View

2.
Ohara T, Doi Y, Ninomiya T, Hirakawa Y, Hata J, Iwaki T . Glucose tolerance status and risk of dementia in the community: the Hisayama study. Neurology. 2011; 77(12):1126-34. DOI: 10.1212/WNL.0b013e31822f0435. View

3.
Euser S, Sattar N, Witteman J, Bollen E, Sijbrands E, Hofman A . A prospective analysis of elevated fasting glucose levels and cognitive function in older people: results from PROSPER and the Rotterdam Study. Diabetes. 2010; 59(7):1601-7. PMC: 2889758. DOI: 10.2337/db09-0568. View

4.
Gispen W, Biessels G . Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci. 2000; 23(11):542-9. DOI: 10.1016/s0166-2236(00)01656-8. View

5.
Hurd M, Martorell P, Delavande A, Mullen K, Langa K . Monetary costs of dementia in the United States. N Engl J Med. 2013; 368(14):1326-34. PMC: 3959992. DOI: 10.1056/NEJMsa1204629. View